CN114681667A - Preparation method of drug-loaded sustained-release stent for filling bone defects with anti-osteosarcoma - Google Patents

Preparation method of drug-loaded sustained-release stent for filling bone defects with anti-osteosarcoma Download PDF

Info

Publication number
CN114681667A
CN114681667A CN202210142122.9A CN202210142122A CN114681667A CN 114681667 A CN114681667 A CN 114681667A CN 202210142122 A CN202210142122 A CN 202210142122A CN 114681667 A CN114681667 A CN 114681667A
Authority
CN
China
Prior art keywords
drug
stent
release
release stent
mbg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
CN202210142122.9A
Other languages
Chinese (zh)
Inventor
陈世杰
曾晋
彭毅
黄力平
王栋
仝昭宸
李劲松
苗惊雷
王卫国
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Third Xiangya Hospital of Central South University
Original Assignee
Third Xiangya Hospital of Central South University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Third Xiangya Hospital of Central South University filed Critical Third Xiangya Hospital of Central South University
Priority to CN202210142122.9A priority Critical patent/CN114681667A/en
Publication of CN114681667A publication Critical patent/CN114681667A/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/12—Phosphorus-containing materials, e.g. apatite
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/02—Inorganic materials
    • A61L27/10—Ceramics or glasses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/16—Macromolecular materials obtained by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/18—Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/14—Macromolecular materials
    • A61L27/20—Polysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/216—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials with other specific functional groups, e.g. aldehydes, ketones, phenols, quaternary phosphonium groups
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/20—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices containing or releasing organic materials
    • A61L2300/23—Carbohydrates
    • A61L2300/236—Glycosaminoglycans, e.g. heparin, hyaluronic acid, chondroitin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/412—Tissue-regenerating or healing or proliferative agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/40—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a specific therapeutic activity or mode of action
    • A61L2300/416—Anti-neoplastic or anti-proliferative or anti-restenosis or anti-angiogenic agents, e.g. paclitaxel, sirolimus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2300/00—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices
    • A61L2300/60—Biologically active materials used in bandages, wound dressings, absorbent pads or medical devices characterised by a special physical form
    • A61L2300/602—Type of release, e.g. controlled, sustained, slow
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2430/00—Materials or treatment for tissue regeneration
    • A61L2430/02—Materials or treatment for tissue regeneration for reconstruction of bones; weight-bearing implants

Abstract

The invention relates to the preparation of a drug-loaded sustained-release stent, in particular to a preparation method of a drug-loaded sustained-release stent for filling bone defects with anti-osteosarcoma, which comprises the steps of preparing a beta-tricalcium phosphate stent, and immersing the beta-tricalcium phosphate stent into a solution prepared by MBG to obtain an MBG/beta-tricalcium phosphate composite stent; immersing the composite scaffold into a hydrogel solution prepared by chitosan to obtain the composite scaffold attached with the chitosan; preparing adriamycin sustained-release microsphere suspension, and immersing the composite stent attached with the chitosan into the suspension to obtain the adriamycin-loaded sustained-release stent. The preparation method loads the adriamycin with good osteosarcoma resistance on the MBG/beta-tricalcium phosphate composite stent, and after the stent is implanted, the bone defect can be filled, the osteogenesis is promoted, and the reconstruction is accelerated; moreover, the adriamycin can be slowly released in a local space of the bone defect of the excision of the osteosarcoma so as to reduce the recurrence risk of the osteosarcoma.

Description

Preparation method of drug-loaded sustained-release stent for filling bone defects with anti-osteosarcoma
Technical Field
The invention relates to preparation of a drug-loaded slow-release stent, in particular to a preparation method of a drug-loaded slow-release stent for filling bone defects with anti-osteosarcoma.
Background
Osteosarcoma is the most common primary malignant bone tumor, and the current treatment mainly comprises surgical in-situ resection and chemotherapy before and after operation, but the recurrence or bone defect caused by osteosarcoma cannot be avoided. In clinical procedures, chemotherapy is still required after the reconstruction of bone defects after local surgery, patients need chemotherapy drugs for the whole body, and side effects, drug resistance and local recurrence of the chemotherapy drugs are still the main challenges for the treatment of osteosarcoma. At present, the drug sustained-release microspheres can well embed the drug, control the release rate of the drug, improve the utilization rate of the drug and reduce the harm of the drug to the whole body. Therefore, drug-loaded microspheres are widely studied and applied to the medical field. The drug-loaded microspheres can be formed by adsorbing the microspheres in microspheres formed by a high polymer material, or uniformly distributing drugs in the high polymer material to form the microspheres, the drugs are embedded by the microspheres and slowly released locally, the drug concentration can be maintained in an effective tumor killing range within a long time by regulating and controlling the drug release speed, and the drug effect is well prolonged; meanwhile, adverse reaction and drug resistance of the drug to the whole body are reduced, and the activity and the utilization rate of the drug are improved. But because the polymer material does not promote osteogenesis, the bone defect left after the polymer material is degraded is not repaired in time.
Disclosure of Invention
Aiming at the technical problems, the invention provides an effective preparation method of a drug-loaded slow-release stent for filling bone defects with anti-osteosarcoma for the treatment of reconstruction after osteosarcoma excision.
The technical scheme adopted by the invention for solving the technical problems is as follows: a preparation method of a drug-loaded slow-release stent for filling bone defects with anti-osteosarcoma comprises the following steps:
(1) preparing a beta-tricalcium phosphate scaffold, and immersing the beta-tricalcium phosphate scaffold into a solution prepared by MBG to obtain an MBG/beta-tricalcium phosphate composite scaffold;
(2) immersing the composite scaffold into a hydrogel solution prepared by chitosan to obtain the composite scaffold attached with the chitosan;
(3) preparing adriamycin sustained-release microsphere suspension, and immersing the composite stent attached with the chitosan into the suspension to obtain the adriamycin-loaded sustained-release stent.
Preferably, the beta-tricalcium phosphate scaffold is prepared by a 3D printing method.
Preferably, the MBG solution is prepared by adding MBG powder into ethanol to prepare 2g/L of MBG solution.
Preferably, the particle size of the MBG powder is 50-80 microns.
Preferably, the beta-tricalcium phosphate scaffold is immersed in the solution prepared by MBG for 1 hour, and then taken out and dried at a constant temperature of 20 ℃ to obtain the composite scaffold with the MBG particles attached to the surface.
Preferably, the hydrogel solution prepared by chitosan is a chitosan hydrogel solution with the concentration of 6g/L prepared by mixing chitosan and acetic acid.
Preferably, the composite scaffold is immersed in the chitosan hydrogel solution for 1 hour, taken out, put into an oven for drying at 37 ℃, then rinsed with ultrapure water, put into a 5% NaOH solution for 30min, and rinsed again and again with ultrapure water to obtain the composite scaffold with chitosan attached.
Preferably, the adriamycin sustained-release microsphere suspension is prepared by dissolving adriamycin in deionized water, adding polylactic acid-glycolic acid copolymer and dichloromethane for ultrasonic emulsification, adding PVA solution, stirring, standing to obtain microsphere precipitate, cleaning the microsphere precipitate, and adding distilled water to prepare 2g/L suspension.
Preferably, the mass ratio of the adriamycin to the polylactic acid-glycolic acid copolymer is (0.4-4): 1.
Preferably, the composite stent with the chitosan attached is immersed in the suspension for 1 hour at 37 ℃, and then taken out for freezing and drying at-20 ℃ to obtain the sustained-release stent loaded with the adriamycin.
According to the technical scheme, the adriamycin with good osteosarcoma resistance is loaded on the MBG/beta-tricalcium phosphate composite stent, and after the stent is implanted, the bone defect can be filled, the osteogenesis is promoted, and the reconstruction is accelerated; moreover, the adriamycin can be slowly released in the local space of the bone defect of the excision of the osteosarcoma so as to reduce the risk of recurrence of the osteosarcoma. Therefore, the invention provides the slow release stent which can effectively release the medicament for resisting tumors and promote osteogenesis osteoinduction, and the slow release stent can be used for synergistically treating osteosarcoma and promoting bone regeneration, so that the side effects of chemotherapeutic medicaments for treating the osteosarcoma are reduced.
Detailed Description
The present invention will be described in detail with reference to the following examples, which are illustrative of the present invention and are not to be construed as limiting the present invention.
The invention provides a preparation method of a drug-loaded slow-release stent for filling bone defects with anti-osteosarcoma, which comprises the following steps:
firstly, preparing a beta-tricalcium phosphate support by adopting a 3D printing method, wherein the specific 3D printing preparation technology is the prior art and is not described herein again; then immersing the beta-tricalcium phosphate stent into a solution prepared by MBG to obtain an MBG/beta-tricalcium phosphate composite stent; the Mesoporous Bioactive Glass (MBG) is an inorganic material, and pores of the mesoporous bioactive glass are favorable for being attached to a beta-tricalcium phosphate support and can provide a good environment for cell migration and adhesion; and meanwhile, MBG degraded products are nontoxic and harmless and can be metabolized by a human body. In the implementation process, the MBG preparation solution is prepared by adding MBG powder into ethanol to prepare 2g/L of MBG solution, and the concentration can accelerate the particles to be attached to the beta-tricalcium phosphate scaffold; and the particle size of the MBG powder is preferably 50-80 microns to provide pores of sufficient size. Specifically, the beta-tricalcium phosphate scaffold is immersed in a solution prepared by MBG for 1 hour, and then taken out and dried at a constant temperature of 20 ℃ to obtain the composite scaffold with the MBG particles attached to the surface, so that the specific surface area of the composite scaffold is increased, and more drugs can be loaded.
And then, immersing the composite scaffold attached with the MBG particles into a hydrogel solution prepared by chitosan to obtain the MBG/beta-tricalcium phosphate composite scaffold attached with the chitosan. The chitosan not only has broad-spectrum antibacterial property, but also is a slow-release drug delivery carrier. Although chitosan itself has low mechanical strength, it is attached to the MBG/β -tricalcium phosphate composite scaffold of the present invention, which can improve mechanical strength. Because the MBG/beta-tricalcium phosphate composite scaffold is soaked in the chitosan hydrogel, hydrogel molecules can enter and be adsorbed in pores due to the existence of the pores in the MBG, and thus, the mechanical property is improved. In the implementation process, the chitosan hydrogel solution prepared by chitosan is prepared by mixing chitosan and acetic acid, and the concentration of the chitosan hydrogel solution is 6g/L, so that colloidal molecules can enter pores quickly. And immersing the MBG/beta-tricalcium phosphate composite scaffold into a chitosan hydrogel solution for 1 hour, taking out, putting into an oven for drying at 37 ℃, washing the dried composite scaffold with ultrapure water, then putting into a 5% NaOH solution for 30min to neutralize the acidity of acetic acid, and then repeatedly washing with ultrapure water for at least 3 times to obtain the MBG/beta-tricalcium phosphate composite scaffold attached with chitosan.
Preparing adriamycin sustained-release microsphere suspension, immersing the composite stent attached with the chitosan into the suspension to obtain a sustained-release stent loaded with adriamycin, wherein some adriamycin sustained-release microspheres are filled in pores of MBG particles and some adriamycin sustained-release microspheres are filled in gaps formed by the chitosan and the MBG particles on the sustained-release stent, so that the loading capacity of the adriamycin sustained-release microspheres is greatly increased. Specifically, the adriamycin sustained-release microsphere suspension is prepared by dissolving adriamycin in deionized water, adding polylactic acid-glycolic acid copolymer and dichloromethane for ultrasonic emulsification, adding PVA solution, stirring, standing to obtain microsphere precipitate, cleaning the microsphere precipitate, and adding distilled water to prepare 2g/L suspension. Preferably, the mass ratio of the adriamycin to the polylactic acid-glycolic acid copolymer is (0.4-4): 1, which is more favorable for the slow release effect of the adriamycin.
The composite stent attached with the chitosan is immersed in the suspension for 1 hour at the temperature of 37 ℃, and then taken out for freezing and drying at the temperature of-20 ℃, so that the sustained-release stent loaded with the adriamycin is obtained. In the implementation process, the prepared adriamycin sustained-release microspheres adopt polylactic acid-glycolic acid copolymer, and the hydrophobic property of the polymer can be obviously improved after the MBG is compounded with the polymer, so that the biocompatibility is greatly improved, and the reliability of the adriamycin sustained-release microspheres in adhesion is ensured. Therefore, the invention provides the chitosan MBG/beta-tricalcium phosphate composite stent attached with the adriamycin microspheres, which can effectively release the medicament for resisting tumors and promote osteogenesis bone induction, thereby reducing the side effect of chemotherapeutic medicaments for treating osteosarcoma. In the implementation process, the chitosan MBG/beta-tricalcium phosphate composite stent attached with the adriamycin microspheres prepared by the invention has good treatment effect by performing experiments on the mechanical property, the in vivo and in vitro drug slow release performance, the osteogenesis effect and the like.

Claims (10)

1. A preparation method of a drug-loaded slow-release stent for filling bone defects with anti-osteosarcoma is characterized by comprising the following steps:
(1) preparing a beta-tricalcium phosphate scaffold, and immersing the beta-tricalcium phosphate scaffold into a solution prepared by MBG to obtain an MBG/beta-tricalcium phosphate composite scaffold;
(2) immersing the composite scaffold into a hydrogel solution prepared by chitosan to obtain the composite scaffold attached with the chitosan;
(3) preparing adriamycin sustained-release microsphere suspension, and immersing the composite stent attached with the chitosan into the suspension to obtain the adriamycin-loaded sustained-release stent.
2. The preparation method of the drug-loaded slow-release stent for filling bone defects with osteosarcoma according to claim 1, wherein the drug-loaded slow-release stent comprises the following steps: the beta-tricalcium phosphate scaffold is prepared by a 3D printing method.
3. The preparation method of the drug-loaded slow-release stent for filling bone defects with osteosarcoma according to claim 1, wherein the drug-loaded slow-release stent comprises the following steps: the MBG solution is prepared by adding MBG powder into ethanol to prepare 2g/L of MBG solution.
4. The preparation method of the drug-loaded slow-release stent for filling bone defects with osteosarcoma according to claim 3, wherein the drug-loaded slow-release stent comprises the following steps: the particle size of the MBG powder is 50-80 microns.
5. The preparation method of the drug-loaded slow-release stent for filling bone defects with osteosarcoma according to claim 4, wherein the drug-loaded slow-release stent comprises the following steps: and soaking the beta-tricalcium phosphate scaffold into a solution prepared by MBG for 1 hour, and then taking out the scaffold and drying the scaffold at a constant temperature of 20 ℃ to obtain the composite scaffold with the MBG particles attached to the surface.
6. The preparation method of the drug-loaded slow-release stent for filling bone defects with osteosarcoma according to claim 1, wherein the drug-loaded slow-release stent comprises the following steps: the hydrogel solution prepared from chitosan is a chitosan hydrogel solution with the concentration of 6g/L prepared by mixing chitosan and acetic acid.
7. The preparation method of the drug-loaded slow-release stent for filling bone defects with osteosarcoma according to claim 6, wherein the drug-loaded slow-release stent comprises the following steps: and soaking the composite scaffold in the chitosan hydrogel solution for 1 hour, taking out, putting into an oven for drying at 37 ℃, then washing with ultrapure water, putting into a 5% NaOH solution for 30min, and repeatedly washing with ultrapure water to obtain the composite scaffold attached with chitosan.
8. The preparation method of the drug-loaded slow-release stent for filling bone defects with osteosarcoma according to claim 1, wherein the drug-loaded slow-release stent comprises the following steps: the adriamycin sustained-release microsphere suspension is prepared by dissolving adriamycin in deionized water, adding polylactic acid-glycolic acid copolymer and dichloromethane for ultrasonic emulsification, adding PVA solution, stirring, standing to obtain microsphere precipitate, cleaning the microsphere precipitate, and adding distilled water to prepare 2g/L suspension.
9. The preparation method of the drug-loaded slow-release stent for filling bone defects with osteosarcoma according to claim 8, wherein the drug-loaded slow-release stent comprises the following steps: the mass ratio of the adriamycin to the polylactic acid-glycolic acid copolymer is (0.4-4) to 1.
10. The method for preparing the drug-loaded slow-release stent for filling bone defects with osteosarcoma according to claim 9, wherein the drug-loaded slow-release stent comprises: and (3) immersing the composite stent attached with the chitosan into the suspension for 1 hour at the temperature of 37 ℃, taking out the composite stent and freezing and drying the composite stent at the temperature of-20 ℃ to obtain the sustained-release stent loaded with the adriamycin.
CN202210142122.9A 2022-02-16 2022-02-16 Preparation method of drug-loaded sustained-release stent for filling bone defects with anti-osteosarcoma Withdrawn CN114681667A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202210142122.9A CN114681667A (en) 2022-02-16 2022-02-16 Preparation method of drug-loaded sustained-release stent for filling bone defects with anti-osteosarcoma

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202210142122.9A CN114681667A (en) 2022-02-16 2022-02-16 Preparation method of drug-loaded sustained-release stent for filling bone defects with anti-osteosarcoma

Publications (1)

Publication Number Publication Date
CN114681667A true CN114681667A (en) 2022-07-01

Family

ID=82136627

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202210142122.9A Withdrawn CN114681667A (en) 2022-02-16 2022-02-16 Preparation method of drug-loaded sustained-release stent for filling bone defects with anti-osteosarcoma

Country Status (1)

Country Link
CN (1) CN114681667A (en)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04242658A (en) * 1990-12-28 1992-08-31 Kyocera Corp Vivi-implant material and manufacture thereof
CN101791436A (en) * 2010-04-15 2010-08-04 四川大学 Biomedical material with porous calcium phosphate-chitosan composite coating
CN102188749A (en) * 2010-03-10 2011-09-21 中国科学院上海硅酸盐研究所 3D porous bracket with mesoporous biological glass coating and preparation method thereof
CN105311673A (en) * 2015-10-16 2016-02-10 中国科学院上海硅酸盐研究所 3D (three-dimensional) printing mesoporous bioactivity glass modified biological ceramic support, and preparation method and application thereof
CN108671269A (en) * 2018-05-24 2018-10-19 上海应用技术大学 A kind of carried medicine sustained-release holder complex for treating infectious bone defect

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH04242658A (en) * 1990-12-28 1992-08-31 Kyocera Corp Vivi-implant material and manufacture thereof
CN102188749A (en) * 2010-03-10 2011-09-21 中国科学院上海硅酸盐研究所 3D porous bracket with mesoporous biological glass coating and preparation method thereof
CN101791436A (en) * 2010-04-15 2010-08-04 四川大学 Biomedical material with porous calcium phosphate-chitosan composite coating
CN105311673A (en) * 2015-10-16 2016-02-10 中国科学院上海硅酸盐研究所 3D (three-dimensional) printing mesoporous bioactivity glass modified biological ceramic support, and preparation method and application thereof
CN108671269A (en) * 2018-05-24 2018-10-19 上海应用技术大学 A kind of carried medicine sustained-release holder complex for treating infectious bone defect

Similar Documents

Publication Publication Date Title
US8906403B2 (en) Biomaterials carrying cyclodextrins having improved absorption properties and used for the progressive and delayed release of therapeutic molecules
Khor et al. Implantable applications of chitin and chitosan
JP5611978B2 (en) Bioabsorbable foam tissue dressing
JP5649455B2 (en) Implantable products containing nanoparticles
US20130045266A1 (en) Method for preparing polymeric biomaterials having immobilized drug delivery system comprising bioactive molecules loaded particle carrier
WO2014079198A1 (en) Degradable wound-repairing material and preparation method thereof
US20130164346A1 (en) Method for preparing biomedical metal alloy material with multi-drug delivery system
Soundrapandian et al. Organic–inorganic composites for bone drug delivery
WO2022012339A1 (en) Method for constructing bone morphogenetic protein sustained-release system
JP6158286B2 (en) Cross-linked polysaccharide beads and their biomedical use
WO2009049494A1 (en) An artificial stent and its preparation method
WO2008016163A1 (en) Crosslinked gelatin gel multilayered structure, carrier for bioactive factor, preparation for release of bioactive factor, and their production methods
Jennings et al. Chitosan coatings to control release and target tissues for therapeutic delivery
CA3047157A1 (en) A medical implant and a method of coating a medical implant
JP5514222B2 (en) In vivo drug sustained release carrier material comprising hydrogel crosslinked with ionizing radiation and method for producing the same
Guo et al. Recent advances in the medical applications of hemostatic materials
Wei et al. Development of an antibacterial bone graft by immobilization of levofloxacin hydrochloride-loaded mesoporous silica microspheres on a porous scaffold surface
JP2010046249A (en) Hard tissue filling material
CN113633826A (en) Bone repair biological material containing high-activity bone growth promoting factor and application
Pelegrino et al. Chitosan-Based Nanomaterials for Skin Regeneration.
CN113546219A (en) 3D printing medicine-carrying bone defect filler stent and preparation method and application thereof
KR20170056783A (en) Bone graft material in which antibiotics and growth factor
Wang et al. Using scaffolds as drug delivery systems to treat bone tumor
Klara et al. How efficient are alendronate-nano/biomaterial combinations for anti-osteoporosis therapy? An evidence-based review of the literature
Bordone et al. Management of bone diseases: Looking at scaffold-based strategies for drug delivery

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WW01 Invention patent application withdrawn after publication
WW01 Invention patent application withdrawn after publication

Application publication date: 20220701